PMID- 31813467
OWN - NLM
STAT- MEDLINE
DCOM- 20200402
LR  - 20200402
IS  - 1538-2990 (Electronic)
IS  - 0002-9629 (Linking)
VI  - 358
IP  - 6
DP  - 2019 Dec
TI  - Evaluation of Efficacy and Safety for Lentinan in the Control of the Malignant 
      Pleural Effusions via Intrapleural Injection.
PG  - 400-411
LID - S0002-9629(19)30347-7 [pii]
LID - 10.1016/j.amjms.2019.09.009 [doi]
AB  - BACKGROUND: Many studies have investigated the efficacy and safety of lentinan 
      combined with cisplatin versus cisplatin alone for controlling malignant pleural 
      effusion (MPE). This study is a meta-analysis of available evidence. MATERIALS 
      AND METHODS: Seventeen studies reporting lentinan combined with cisplatin versus 
      cisplatin alone for controlling MPE were reviewed. Pooled odds ratios and hazard 
      ratio with 95% confidence intervals were calculated using the fixed effects model 
      of meta-analysis. RESULTS: The overall response rate (ORR) of lentinan combined 
      with cisplatin for controlling MPE was significantly higher than that of 
      cisplatin alone (P < 0.001). In addition, lentinan combined with cisplatin showed 
      a better benefit of quality of life (QOL) compared with cisplatin alone (P < 
      0.001). The main adverse effects (AEs) found in the control plan were 
      hematological reactions, nausea/vomiting, chest pain and fever. However, the 
      presence of lentinan did not have an extra influence on the incidence of AEs (P > 
      0.05). CONCLUSIONS: Intrapleural injection of lentinan combined with cisplatin 
      had a better benefit of ORR and QOL for controlling MPE, compared with cisplatin 
      alone. Moreover, lentinan combined with cisplatin had a similar incidence of AEs 
      with cisplatin alone.
CI  - Copyright (c) 2019 Southern Society for Clinical Investigation. Published by 
      Elsevier Inc. All rights reserved.
FAU - Congcong, Qi
AU  - Congcong Q
AD  - Department of Respiratory Medicine.
FAU - Hengting, Zhu
AU  - Hengting Z
AD  - Department of Critical Care Medicine.
FAU - Shuhui, Li
AU  - Shuhui L
AD  - Department of Cardiology and.
FAU - Fang, Yuan
AU  - Fang Y
AD  - Institute of Clinical Pharmacy & Pharmacology, Jining NO.1 People's Hospital, 
      Jining, China.
FAU - Shan, Wang
AU  - Shan W
AD  - Institute of Clinical Pharmacy & Pharmacology, Jining NO.1 People's Hospital, 
      Jining, China. Electronic address: ws568research@sohu.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191001
PL  - United States
TA  - Am J Med Sci
JT  - The American journal of the medical sciences
JID - 0370506
RN  - 0 (Antineoplastic Agents)
RN  - 37339-90-5 (Lentinan)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Cisplatin/administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Lentinan/administration & dosage/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pleura
MH  - Pleural Effusion, Malignant/*drug therapy
MH  - Quality of Life
MH  - Young Adult
OTO - NOTNLM
OT  - Cisplatin
OT  - Intrapleural injection
OT  - Lentinan
OT  - Malignant pleural effusion
OT  - Meta-analysis
EDAT- 2019/12/10 06:00
MHDA- 2020/04/03 06:00
CRDT- 2019/12/10 06:00
PHST- 2018/12/14 00:00 [received]
PHST- 2019/09/24 00:00 [revised]
PHST- 2019/09/26 00:00 [accepted]
PHST- 2019/12/10 06:00 [entrez]
PHST- 2019/12/10 06:00 [pubmed]
PHST- 2020/04/03 06:00 [medline]
AID - S0002-9629(19)30347-7 [pii]
AID - 10.1016/j.amjms.2019.09.009 [doi]
PST - ppublish
SO  - Am J Med Sci. 2019 Dec;358(6):400-411. doi: 10.1016/j.amjms.2019.09.009. Epub 
      2019 Oct 1.